B J Dicken1, D F Billmire2, B Rich3, F K Hazard4, M Nuño5, M Krailo5, N Fallahazad6, F Pashankar6, F Shaikh7, A L Frazier8. 1. University of Alberta, Stollery Children's Hospital, Edmonton, Alberta, Canada. Electronic address: bdicken@ualberta.ca. 2. Surgery, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, United States of America. 3. Division of Pediatric Surgery, Cohen Children's Hospital, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, United States of America. 4. Pathology and Pediatrics, Department of Pathology, Stanford University, Stanford, CA, United States of America. 5. Department of Population and Public Health Sciences, University of Southern California, United States of America; Children's Oncology Group, Public Health Institute, United States of America. 6. Department of Pediatrics, Yale University School of Medicine, United States of America. 7. Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada. 8. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, United States of America.
Abstract
PURPOSE: In adult women, most malignant ovarian tumors are epithelial in origin. The use of intra-operative frozen section to distinguish between benign and malignant histology is reliable in guiding operative decision-making to determine the extent of surgical staging required. Pediatric and adolescent patients with ovarian masses have a much different spectrum of pathology with most tumors arising from germ cell precursors. This review was undertaken to assess the concordance between the intra-operative frozen section and the final diagnosis as an aid to guide extent of surgical staging in a group of pediatric and adolescent patients with malignant ovarian germ cell tumors. METHODS: Records of patients aged 0 to 20 years with malignant ovarian germ cell tumors enrolled on Children's Oncology Group study AGCT0132 were reviewed. Pathology reports from patients who had both intra-operative frozen section diagnosis and final paraffin section diagnosis were compared using descriptive statistics. By inclusion criteria for the study, all patients had a final diagnosis of malignancy with required yolk sac tumor, choriocarcinoma or embryonal carcinoma histology. Available central review of pathology final paraffin section slides were compared with final institution pathology reports. RESULTS: Of 131 eligible patients with ovarian germ cell tumors, 60 (45.8%) had both intra-operative frozen section and final paraffin section diagnoses available. Intra-operative frozen section diagnoses were classified as: incorrect diagnosis of benign tumor (13.3%), confirmation of malignancy (61.7%), immature teratoma (16.7%), germ cell tumor not otherwise specified (5%) and no diagnosis provided (3.3%). Intra-operative frozen section was incorrect in 23 of 60 (38.3%) patients evaluated. Central pathology review was concordant with the final institution pathology diagnosis in 76.3% of patients. Central pathology review identified additional germ cell tumor components in 23.7% of patients. CONCLUSIONS: In pediatric and adolescent patients with a confirmed final diagnosis of ovarian germ cell malignancy, intra-operative frozen section diagnosis is not reliable to inform the extent of surgical staging required. Central review by an expert germ cell tumor pathologist provides important additional information to guide therapy.
PURPOSE: In adult women, most malignant ovarian tumors are epithelial in origin. The use of intra-operative frozen section to distinguish between benign and malignant histology is reliable in guiding operative decision-making to determine the extent of surgical staging required. Pediatric and adolescent patients with ovarian masses have a much different spectrum of pathology with most tumors arising from germ cell precursors. This review was undertaken to assess the concordance between the intra-operative frozen section and the final diagnosis as an aid to guide extent of surgical staging in a group of pediatric and adolescent patients with malignant ovarian germ cell tumors. METHODS: Records of patients aged 0 to 20 years with malignant ovarian germ cell tumors enrolled on Children's Oncology Group study AGCT0132 were reviewed. Pathology reports from patients who had both intra-operative frozen section diagnosis and final paraffin section diagnosis were compared using descriptive statistics. By inclusion criteria for the study, all patients had a final diagnosis of malignancy with required yolk sac tumor, choriocarcinoma or embryonal carcinoma histology. Available central review of pathology final paraffin section slides were compared with final institution pathology reports. RESULTS: Of 131 eligible patients with ovarian germ cell tumors, 60 (45.8%) had both intra-operative frozen section and final paraffin section diagnoses available. Intra-operative frozen section diagnoses were classified as: incorrect diagnosis of benign tumor (13.3%), confirmation of malignancy (61.7%), immature teratoma (16.7%), germ cell tumor not otherwise specified (5%) and no diagnosis provided (3.3%). Intra-operative frozen section was incorrect in 23 of 60 (38.3%) patients evaluated. Central pathology review was concordant with the final institution pathology diagnosis in 76.3% of patients. Central pathology review identified additional germ cell tumor components in 23.7% of patients. CONCLUSIONS: In pediatric and adolescent patients with a confirmed final diagnosis of ovarian germ cell malignancy, intra-operative frozen section diagnosis is not reliable to inform the extent of surgical staging required. Central review by an expert germ cell tumor pathologist provides important additional information to guide therapy.
Authors: B Cushing; R Giller; A Ablin; L Cohen; J Cullen; E Hawkins; S A Heifetz; M Krailo; S J Lauer; N Marina; P V Rao; F Rescorla; C D Vinocur; R M Weetman; R P Castleberry Journal: Am J Obstet Gynecol Date: 1999-08 Impact factor: 8.661
Authors: Philipp Harter; Jalid Sehouli; Domenica Lorusso; Alexander Reuss; Ignace Vergote; Christian Marth; Jae-Weon Kim; Francesco Raspagliesi; Björn Lampe; Giovanni Aletti; Werner Meier; David Cibula; Alexander Mustea; Sven Mahner; Ingo B Runnebaum; Barbara Schmalfeldt; Alexander Burges; Rainer Kimmig; Giovanni Scambia; Stefano Greggi; Felix Hilpert; Annette Hasenburg; Peter Hillemanns; Giorgio Giorda; Ingo von Leffern; Carmen Schade-Brittinger; Uwe Wagner; Andreas du Bois Journal: N Engl J Med Date: 2019-02-28 Impact factor: 91.245
Authors: Deborah F Billmire; John W Cullen; Frederick J Rescorla; Mary Davis; Marc G Schlatter; Thomas A Olson; Marcio H Malogolowkin; Farzana Pashankar; Doojduen Villaluna; Mark Krailo; Rachel A Egler; Carlos Rodriguez-Galindo; A Lindsay Frazier Journal: J Clin Oncol Date: 2014-01-06 Impact factor: 44.544
Authors: Arin L Madenci; Bat-Sheva Levine; Marc R Laufer; Theonia K Boyd; Stephan D Voss; A Lindsay Frazier; Christopher B Weldon Journal: J Pediatr Surg Date: 2016-04-11 Impact factor: 2.545